Pfizer has effectively dominated the COVID-19 vaccine market in Europe, raking in billions of dollars in the process
By Arsenio Toledo // Jan 26, 2022

Big Pharma company Pfizer has effectively cornered the vaccine market in the European Union, as it is about to provide the bloc with nearly two billion doses of its Wuhan coronavirus (COVID-19) vaccine.

Brighteon.TV

Early last year, Pfizer inked a deal with the EU to provide the 27-nation bloc with 1.8 billion doses of its mRNA vaccines.

This represents the single largest mass purchase of vaccines in world history and could fully vaccinate the entire population of the EU twice over. If each person gets one of the 1.8 billion doses, that would mean roughly 23 percent of the world's population will be injected with the COVID vaccine.

The EU inked this deal with Pfizer just as the Big Pharma company hiked up the price of its vaccine to $23 per dose. This means the EU paid Pfizer over $41 billion for 1.8 billion doses.

Michel Chossudovsky, professor emeritus of economics at the University of Ottawa, asked why the EU would trust a company "which has a criminal record" like Pfizer, going so far as to call it a "reliable partner."

"These shots are not vaccines," he wrote in Global Research. "They are not meant to protect you against the virus."

"The media has failed to remind us that in 2009, Pfizer Inc. pleaded guilty to criminal charges. It was the largest healthcare fraud settlement in the history of the U.S. Department of Justice… The criminality surrounding the 2020-21 mRNA vaccine far surpasses the 2009 fraudulent marketing charges directed against Pfizer," continued Chossudovsky.

"What is at stake is the outright criminalization of the state apparatus, whereby politicians, members of parliament, senior government officials, are routinely bribed, co-opted or threatened to abide by a diabolical project which is literally destroying people's lives worldwide." (Related: EU ADMITS repeatedly taking COVID-19 vaccine boosters could destroy the immune system.)

Europe to be flooded with more Pfizer vaccines

Late last year, as the post-vaccine omicron variant was spreading like wildfire through highly vaccinated Europe, the governments that compose the EU agreed to exercise an option to purchase more than 180 million additional doses of the COVID-19 vaccine from Pfizer.

The vaccine the EU purchased would be a version of the Pfizer vaccine that has been adapted to supposedly better fight against the omicron variant. The Big Pharma company said it began development on a prototype for an omicron-specific vaccine in late November, and it could be ready as early as March.

"The Member States [of the EU] have agreed to trigger a first tranche of over 180 million extra doses of adapted vaccines, in our third contract with BioNTech-Pfizer," announced European Commission President Ursula von der Leyen during a news conference.

A press release from Pfizer a few days later clarified that the deal was for over 200 million additional doses. These 200 million adapted vaccines are in addition to the 450 million regular doses the company already planned to deliver to the EU in 2022.

By the end of the year, Pfizer expects to have delivered 650 million vaccine doses to the EU, or just around a third of the 1.8 billion it promised to the bloc. By the end of 2023, this number is expected to jump to 900 million, with the remaining 900 million up for grabs by EU member states upon request.

More related articles:

Toronto man says Pfizer's COVID-19 vaccine KILLED his healthy, athletic 17-year-old son.

Investigation proves Pfizer vaccine offers less than 1% protection against COVID-19.

EU regulators, WHO call for end to COVID boosters, citing evidence strategy is failing.

Watch this heartbreaking testimony from a mother of two as she talks about her adverse reaction to the Pfizer vaccine.

This video is from the Take Note TV channel on Brighteon.com.

Learn more about Pfizer and its COVID-19 vaccine at Vaccines.news.

Sources include:

GlobalResearch.ca

Reuters.com

Pfizer.com

Brighteon.com



Take Action:
Support NewsTarget by linking to this article from your website.
Permalink to this article:
Copy
Embed article link:
Copy
Reprinting this article:
Non-commercial use is permitted with credit to NewsTarget.com (including a clickable link).
Please contact us for more information.
Free Email Alerts
Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more.

NewsTarget.com © 2022 All Rights Reserved. All content posted on this site is commentary or opinion and is protected under Free Speech. NewsTarget.com is not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. NewsTarget.com assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published on this site. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.

This site uses cookies
News Target uses cookies to improve your experience on our site. By using this site, you agree to our privacy policy.
Learn More
Close
Get 100% real, uncensored news delivered straight to your inbox
You can unsubscribe at any time. Your email privacy is completely protected.